Intrinsic Value of S&P & Nasdaq Contact Us

Seagen Inc. SGEN NASDAQ

NASDAQ Global Select • Healthcare • Biotechnology • US • USD

SharesGrow Score
47/100
2/7 Pass
SharesGrow Intrinsic Value
N/A
Negative cash flow
Analyst Price Target
$171.82
-24.9%

Seagen Inc. (SGEN) generated $-453.75M in operating cash flow for fiscal year 2022. After capital expenditures of $77.34M, free cash flow was $-531.09M.

Free cash flow margin was -27.1% of revenue. Cash conversion ratio was 0.74x, suggesting some earnings are non-cash.

Criteria supported by this page:

  • HEALTH (100/100, Pass) — demonstrate the company can comfortably service its debt
  • MOAT (65/100, Partial) — cash flow generation is present but not at levels indicating a wide moat
  • INCOME (10/100) — Cash conversion ratio was 0.74x suggests some earnings are non-cash items

Overall SharesGrow Score: 47/100 with 2/7 criteria passed.

SharesGrow 7-Criteria Score
47/100
SG Score
View full scorecard →
VALUE
10/100
Price-to-Earnings & upside
→ Valuation
FUTURE
16/100
Analyst consensus
→ Forecast
PAST
25/100
→ Income
HEALTH
100/100
Debt-to-Equity & liquidity
Proven by this page
~
MOAT
65/100
Proven by this page
GROWTH
100/100
→ Income
INCOME
10/100
→ Income
Seagen Inc. Cash Flow History
Metric TTM FY2022 FY2021 FY2020 FY2019
Operating Cash Flow $-540.15M$-453.75M$-499.01M$856.57M$-163.74M
Capital Expenditure $-161.06M$-77.34M$-52.33M$-82.41M$-70.75M
Free Cash Flow $-701.21M$-531.09M$-551.34M$774.16M$-234.49M
Contact Us
🎓
SharesGrow Academy
Learn how to calculate Intrinsic Value and find undervalued stocks.
Weekly live sessions
Send us a message